It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

GSK PLC GSK shares rose 1.06% to £13.34 Tuesday, on what proved to be an all-around dismal trading session for the stock ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...

Teva Pharmaceutical Industries Ltd. ADR 1.42% $19.56B ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.01% of ...

The test used two synovial fluid biomarkers to accurately differentiate osteoarthritis from inflammatory arthritis, but its ...

As 2024 draws to a close, we explore five stocks to buy for a new year that promises opportunity alongside uncertainty ...

A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

A pat­ent dis­pute between GSK sub­si­di­ary ViiV Health­care and Colom­bian reg­u­lat­ors is not cur­rently before the Inter­na­tional Centre for Set­tle­ment of Invest­ment Dis­putes in Wash­ing­ton ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

肖比·拉玛克里希南早期职业生涯的大部分时间都在硅谷度过。作为葛兰素史克（GSK）的首席数字与技术官（CDTO），拉玛克里希南在苹果（Apple）和赛富时（Salesforce）等科技巨头工作了多年，后来转向日益技术化的制药行业。